FDA Approved: PHOTREXA CROSS-LINKING KIT — Supplemental Application (Glaukos Corporation)

View source ↗

Summary

FDA approved a supplemental application for Photrexa Cross-Linking Kit (riboflavin 5-phosphate ophthalmic) from Glaukos Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Ectasia
• Keratoconus

Drugs mentioned

• PHOTREXA CROSS-LINKING KIT (Riboflavin 5-phosphate ophthalmic)

Snippet

SUPPL AP for PHOTREXA CROSS-LINKING KIT (RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC)